$Elevation Oncology(ELEV.US)$ NEWS Elevation Oncology Presents Preclinical Proof-of-Concept Data for HER3-ADC Program at AACR Annual Meeting 2024 Elevation Oncology announces promising preclinical data for its HER3-ADC program, showcasing proof-of-concept results at AACR Annual Meeting 2024. The data demonstrates HER3-dependent cell killing and robust anti-tumor activity in solid tumors with high HER3 expression. The company aims to nominate a development candidate later in 2024.
$Elevation Oncology(ELEV.US)$$Merrimack Pharmaceuticals(MACK.US)$Merrimack Gets $225 Million Milestone Payment, Schedules Meeting For Dissolution Plan MT Newswires· 2 mins ago Merrimack Pharmaceuticals (MACK) said late Wednesday it has received a $225 million milestone payment from Ipsen and called for a special stockholder meeting on May 10 to approve a plan of dissolution. The milestone payment was due from Ipsen after the US Food and Drug Administration approved Onivyde as a first-line...
$Elevation Oncology(ELEV.US)$Elevation Oncology Announced That It Has Expanded Its Ongoing Phase 1 Clinical Trial Of EO-3021 Outside The United States, Dosing The First Patient In Japan
Elevation Oncology股票討論區
NEWS
Elevation Oncology Presents Preclinical Proof-of-Concept Data for HER3-ADC Program at AACR Annual Meeting 2024
Elevation Oncology announces promising preclinical data for its HER3-ADC program, showcasing proof-of-concept results at AACR Annual Meeting 2024. The data demonstrates HER3-dependent cell killing and robust anti-tumor activity in solid tumors with high HER3 expression. The company aims to nominate a development candidate later in 2024.
News
MT Newswires· 2 mins ago
Merrimack Pharmaceuticals (MACK) said late Wednesday it has received a $225 million milestone payment from Ipsen and called for a special stockholder meeting on May 10 to approve a plan of dissolution.
The milestone payment was due from Ipsen after the US Food and Drug Administration approved Onivyde as a first-line...
Update
Still gonna hodl😉
2024 is MOOOOvin up nicely
MOOOOOOOOn!
Still want more tho🥲
暫無評論